Genetic Contribution of CFTR Mutations to Chronic Bronchitis in Children: A Case-Control Study
Masharipova M. S. 1*, Xalimbetov G. S. 1, Khasanova D. A. 1, Nurmuxamedova Rohatoy Abdisharipovna 1
Journal of Angiotherapy 8(10) 1-5 https://doi.org/10.25163/angiotherapy.8109991
Submitted: 05 September 2024 Revised: 24 October 2024 Published: 25 October 2024
Abstract
Background: Chronic bronchitis and bronchial asthma are significant respiratory conditions with complex etiologies influenced by genetic and environmental factors. Mutations in the CFTR gene have been implicated in severe respiratory diseases, underscoring the need to explore their association with these conditions. Methods: This study included 150 children with chronic bronchitis and bronchial asthma, alongside a control group of 60 healthy children. Clinical and genealogical analyses were conducted to evaluate hereditary predisposition. Molecular genetic studies focused on eight common CFTR mutations (F508del, W1282X, and N1303K) using RT-PCR with real-time detection. Statistical analyses, including Hardy-Weinberg equilibrium testing and odds ratio calculations, assessed genetic associations. Results: A hereditary predisposition was identified in 32.3% of parents of affected children. Among the patients, heterozygous CFTR mutations were detected, with F508del in 6.25%, W1282X in 2.1%, and N1303K in 2.1%. These findings suggest a strong genetic influence in the studied population. Conclusion: This study reinforces the role of CFTR mutations in chronic bronchitis and bronchial asthma, highlighting the genetic basis of these conditions. Future research should explore additional candidate genes and unidentified CFTR variants to enhance predictive medicine and personalized treatment strategies.
Keywords: CFTR mutations, chronic bronchitis, hereditary predisposition, pediatric respiratory diseases, genetic etiology
References
Barben, J., et al. (2021). Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Journal of Cystic Fibrosis, 20(5), 810–819. https://doi.org/10.1016/j.jcf.2020.11.006
Diab Cáceres, L., & Zamarrón de Lucas, E. (2023). Cystic fibrosis: Epidemiology, clinical manifestations, diagnosis, and treatment. Medicina Clínica, 161(9), 389–396. https://doi.org/10.1016/j.medcli.2023.06.006
Gembitskaya, T., Chermensky, A., Boitsova, E., & B., E. (2012). Cystic fibrosis today: Progress and problems, promises of etiopathogenetic therapy. Vrach, 23(2).
Kesimer, M., Drummond, M. B., & Boucher, R. C. (2021). Mucus hypersecretion, hyperconcentration, and chronic bronchitis. In Encyclopedia of Respiratory Medicine (2nd ed., Vol. 2, pp. 594–610). https://doi.org/10.1016/B978-0-08-102723-3.00039-1
Miravitlles, M., et al. (2024). Potential systemic effects of acquired CFTR dysfunction in COPD. Respiratory Medicine, 221. https://doi.org/10.1016/j.rmed.2023.107499
Raju, S. V., Solomon, G. M., Dransfield, M. T., & Rowe, S. M. (2016). Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance. Clinics in Chest Medicine, 37(1), 147–158. https://doi.org/10.1016/j.ccm.2015.11.003
Ramananda, Y., Naren, A. P., & Arora, K. (2024). Functional consequences of CFTR interactions in cystic fibrosis. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms25063384
Roesch, E. A., Nichols, D. P., & Chmiel, J. F. (2018). Inflammation in cystic fibrosis: An update. Pediatric Pulmonology, 53(S3), S30–S50. https://doi.org/10.1002/ppul.24129
Solomon, G. M., Raju, S. V., Dransfield, M. T., & Rowe, S. M. (2016). Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis. Annals of the American Thoracic Society, 13(S3), S169–S176. https://doi.org/10.1513/AnnalsATS.201509-601KV
View Dimensions
View Altmetric
Save
Citation
View
Share